As previously presented at the 2025 European Society for Medical Oncology (ESMO) Annual Congress, the combination ...

For over a decade, the standard of care for high-risk MDS has remained a class of drugs called hypomethylating agents (HMAs).

Dr. Shune highlights that the growing availability of FDA-approved agents with distinct and complementary mechanisms has ...

Overall, this segment establishes a nuanced view of prognosis that avoids binary categorization. Instead, Dr Shaheen frames ...

Dr. Shune concludes the discussion by focusing on safety, sequencing, and practical considerations for incorporating ...

The FDA has updated the safety labeling for the chemotherapeutic agents capecitabine (Xeloda) and fluorouracil (5-FU) to ...

Experts debate MMR/p53 testing, liquid biopsy, and immunotherapy sequencing in endometrial cancer, refining prognosis and relapse treatment.

In a milestone for the hematologic oncology landscape, the first patient has been dosed in a phase 1/2 clinical trial (NCT07220616) evaluating DS3790, a potential first-in-class antibody-drug ...

A trial found that off-the-shelf TRX103 Tr1 cells were safe to use after mismatched donor stem cell transplant, showing engraftment and dose-dependent expansion and persistence.

In the first multicenter retrospective study of the tumor-infiltrating lymphocyte (TIL) therapy, there was an overall response rate (ORR) of 44% among 41 treated patients, with higher responses in ...

Dr. Shaheen discusses a complex pancreatic neuroendocrine tumor case, emphasizing tailored treatment goals that balance tumor control and quality of life.